Articles tagged with: Viruses

London leads the way in advanced prostate cancer research

Posted in General News, Grants & Awards Published by Administrator 25 January 2019

London leads the way in advanced prostate cancer research

Dr Gunnel Halldén is leading a new pioneering study funded by Prostate Cancer UK, as part of the charity’s Research Innovation Awards scheme.

Using a modified adenovirus to overcome treatment resistance in prostate cancer

Posted in General News, Publications Published by Bethan Warman 27 April 2018

Using a modified adenovirus to overcome treatment resistance in prostate cancer

Researchers from BCI’s Centre for Molecular Oncology, led by Dr Gunnel Halldén, have identified a mechanism by which a modified flu-like virus, called AdDD, is able to negate resistance to a drug called mitoxantrone and increase tumour cell killing in prostate cancer models. This mechanism is dependent on B-cell lymphoma 2 (Bcl-2)- a protein involved in the regulation of cell death (apoptosis).

Recent statistics have shown that prostate cancer is now the third biggest cancer killer in the UK, claiming the life of one man every 45 minutes. Here at the BCI, prostate cancer is a key focus of research and our researchers endeavour to identify factors that influence prostate cancer progression and therapeutic response.

Researchers use flu-like virus to attack pancreatic cancer

Posted in General News, Publications Published by Bethan Warman 25 January 2018

Researchers use flu-like virus to attack pancreatic cancer

A flu-like virus has now been used in experiments to successfully inhibit the growth of pancreatic cancer, according to an early study by researchers at the Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL).

The study funded by the charity Pancreatic Cancer Research Fund, led by Dr Gunnel Halldén based at the Centre for Molecular Oncology, and including UK colleagues at Cardiff University, suggests that the new technique could potentially become a promising new treatment for patients with the aggressive disease, and could be combined with existing chemotherapy to improve chances of survival.

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.